Provided by Tiger Fintech (Singapore) Pte. Ltd.

ENGENE HOLDINGS INC

4.62
-0.1300-2.74%
Post-market: 4.44-0.1799-3.89%16:27 EDT
Volume:24.87K
Turnover:116.08K
Market Cap:236.11M
PE:-2.76
High:4.85
Open:4.80
Low:4.56
Close:4.75
52wk High:11.00
52wk Low:2.65
Shares:51.11M
Float Shares:18.85M
Volume Ratio:0.29
T/O Rate:0.13%
Dividend:0.00
Dividend Rate:0.02%
EPS(TTM):-1.6750
EPS(LYR):-1.4595
ROE:-33.97%
ROA:-20.35%
PB:1.04
PE(LYR):-3.17

Loading ...

Company Profile

Company Name:
ENGENE HOLDINGS INC
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
57
Office Location:
4868 Rue Levy,Suite 220,Montreal,Quebec,Canada
Zip Code:
H4R 2P1
Fax:
- -
Introduction:
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Directors

Name
Position
Richard Glickman
Chairman of the Board
Ronald H. W. Cooper
Chief Executive Officer, President and Director
Gerald Brunk
Independent Director
Lota Zoth
Independent Director
Michael Heffernan
Independent Director
Paul J. Hastings
Independent Director
Philip Astley Sparke
Independent Director
William Grossman
Independent Director
Wouter Joustra
Independent Director

Shareholders

Name
Position
Ronald H. W. Cooper
Chief Executive Officer, President and Director
Ryan Daws
Chief Financial Officer
Alex Nichols
Chief Strategy and Operations Officer
Anthony T. Cheung
Chief Scientific Officer
Joan Connolly
Chief Technology Officer
Lee G. Giguere
Chief Legal Officer and Corporate Secretary
Raj S. Pruthi
Chief Medical Officer